ZMYND10 and cancer: Furthermore, cancers with high expression of the FREM1 gene were sensitive to XAV939 and dasatinib and resistant to SB590885 and gemcitabine, and cancers with high expression of ZMYND10 were resistant to XAV939, gemcitabine, and SB590885 (Figure 9).